Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.

abstract：PURPOSE:Since the hypothesis that solid tumors cause angiogenesis by secreting pro-angiogenic factors was introduced, research on angiogenesis has proceeded continuously. Development of inhibitors targeting the angiogenic tyrosine kinases, to block downstream signal transduction pathways, has become an important approa...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang J,Zhang L,Wang Y,Zhao G

更新日期：2016-05-01 00:00:00

abstract：:GR63178A is the second pentacyclic pyrroloquinone to enter clinical trials as an anticancer drug. We developed a reversed-phase, gradient-elution high-performance liquid chromatography (HPLC) method along with a Bond Elut C2 mini-column sample-preparation technique for the analysis of GR63178A, its 9-hydroxy-metabolit...

journal_title：Cancer chemotherapy and pharmacology

authors： Cummings J,French RC,MacLellan A,Smyth JF

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase enzyme. Combination of veliparib and temozolomide was well-tolerated and demonstrated clinical activity in older patients with relapsed or refractory acute myeloid leukemia (AML) or AML arising from pre-existing myeloid malignancies. We aimed to perf...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh R,Mehrotra S,Gopalakrishnan M,Gojo I,Karp JE,Greer JM,Chen A,Piekarz R,Kiesel BF,Gobburu J,Rudek MA,Beumer JH,ETCTN-6745 study team.

更新日期：2019-02-01 00:00:00

abstract：PURPOSE:To study the dual mechanism of action of FD137, a 3,3-disubstituted nitrosourea designed to block signaling mediated by the epidermal growth factor receptor (EGFR) on its own and to be hydrolyzed to an inhibitor of EGFR plus a DNA-damaging species. MATERIALS AND METHODS:HPLC was used to determine the half-life...

journal_title：Cancer chemotherapy and pharmacology

authors： Qiu Q,Dudouit F,Matheson SL,Brahimi F,Banerjee R,McNamee JP,Jean-Claude BJ

更新日期：2003-01-01 00:00:00

abstract：:Two patients with acute promyelocytic leukemia in first relapse received mitoxantrone 12 mg/m2/day for 5 days. Both patients received IV heparin with replacement of platelets and coagulation factors for control of disseminated intravascular coagulopathy. Both have achieved a complete remission after one course of trea...

journal_title：Cancer chemotherapy and pharmacology

authors： Mittelman A,Rieber E,Friedland ML,Arlin ZA

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:To evaluate the population pharmacokinetics of pemetrexed disodium in cancer patients enrolled in four different open-label, multicenter, nonrandomized phase II studies. METHODS:Pemetrexed disodium was administered as a 10-min intravenous infusion (600 mg/m2) every 21 days. A total of four blood samples were t...

journal_title：Cancer chemotherapy and pharmacology

authors： Ouellet D,Periclou AP,Johnson RD,Woodworth JR,Lalonde RL

更新日期：2000-01-01 00:00:00

abstract：PURPOSE:Some clinical studies on etoposide (Eto) have shown marked schedule dependency of the effect (starting at about 1 mg/l) and toxicity (over about 10 mg/l) whereas other studies have not confirmed these results. What are the conclusions we can draw from these inconsistent results when developing new low-dose (LD)...

journal_title：Cancer chemotherapy and pharmacology

authors： Würthwein G,Boos J

更新日期：2002-04-01 00:00:00

abstract：PURPOSE:The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP). METHODS:Previously unt...

journal_title：Cancer chemotherapy and pharmacology

authors： Shin DY,Choi YH,Lee HR,Na II,Yuh YJ,Kim BS,Chung IJ,Bae WK,Shim HJ,Song EK,Yang SH,Kang HJ

更新日期：2016-01-01 00:00:00

abstract：:We investigated the antitumor activity of cis-diammine[1,1-cyclobutanedicarboxylato]platinum(II) (CBDCA, JM8) and cis-dichloro-trans-dihydroxybis(isopropylammine)platinum(IV) (CHIP, JM9) for the cis-DDP-sensitive and -resistant IgM immunocytoma in the LOU/M Wsl rat. The optimal dose for the antitumor effect of cis-dia...

journal_title：Cancer chemotherapy and pharmacology

authors： Steerenberg PA,Vendrik CP,de Jong WH,de Groot G,Fichtinger-Schepman AM,Scheefhals AP,Schornagel JH

更新日期：1988-01-01 00:00:00

abstract：:The pharmacokinetics of diacetyldianhydrogalactitol (DADAG) was compared in mice, rats, and humans. The ratios of human therapeutic dose (ThD) to the LD10 were 8 and 5 in mice and rats, respectively. The ratios of the corresponding AUCs of DADAG were 20 and 17, whereas those of dianhydrogalactitol (DAG), the main, act...

journal_title：Cancer chemotherapy and pharmacology

authors： Kerpel-Fronius S,Erdélyi-Tóth V,Somfai-Relle S,Csetényi J,Kovács P,Ujj G,Kanyár B

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:To differentiate the antagonistic and agonistic effect of toremifene at the level of the hypothalamus-hypophysis axis a leutinizing hormone-releasing hormone (LHRH) test was performed during a phase II clinical trial. METHODS:In 15 postmenopausal patients with advanced breast cancer, follicle-stimulating hormo...

journal_title：Cancer chemotherapy and pharmacology

authors： Számel I,Hindy I,Budai B,Kangas L,Hajba A,Lammintausta R

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL. METHODS:We evaluated ...

journal_title：Cancer chemotherapy and pharmacology

authors： Martell RE,Peterson BL,Cohen HJ,Petros WP,Rai KR,Morrison VA,Elias L,Shepherd L,Hines J,Larson RA,Schiffer CA,Hurwitz HI

更新日期：2002-07-01 00:00:00

abstract：PURPOSE:Platinum-based chemotherapy is the recognized first-line treatment for metastatic nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been established. This phase II study was designed to evaluate the efficacy and safety of a paclitaxel, cisplatin and 5-FU combination in metastatic and/...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen C,Wang FH,An X,Luo HY,Wang ZQ,Liang Y,Zhang L,Li YH

更新日期：2013-02-01 00:00:00

abstract：PURPOSE:Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. Resistant ovarian cancer cells often overexpress bcl-2 or p53 proteins or both. We hypothesized that arsenic compounds, such as As2O3 and As2S3, could also be active...

journal_title：Cancer chemotherapy and pharmacology

authors： Du YH,Ho PC

更新日期：2001-06-01 00:00:00

abstract：PURPOSE:Methotrexate polyglutamates (MTXpg) facilitate incorporation of thioguanine nucleotides into DNA (DNA-TG, the primary cytotoxic thiopurine metabolite and outcome determinant in MTX/6-mercaptopurine treatment of childhood ALL). We hypothesized that mapping erythrocyte levels of MTXpg with 1-6 glutamates and thei...

journal_title：Cancer chemotherapy and pharmacology

authors： Nersting J,Nielsen SN,Grell K,Paerregaard M,Abrahamsson J,Lund B,Jonsson OG,Pruunsild K,Vaitkeviciene G,Kanerva J,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

更新日期：2019-01-01 00:00:00

abstract：PURPOSE:We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94. METHODS:Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 cours...

journal_title：Cancer chemotherapy and pharmacology

authors： Cohen IJ,Toledano H,Stein J,Kollender Y,Fenig E,Konen O,Bar-Sever Z,Issakov J,Feinmesser M,Avigad S,Ash S

更新日期：2019-05-01 00:00:00

abstract：:Increasing the expression of human multidrug resistance (MDR) 1 gene in bone marrow cells to prevent or circumvent bone morrow toxicity from chemotherapy agent is a high priority of dose intensification protocols. In this study, we have used a tumor-bearing model to investigate the chemoprotection effect of MDR1 gene ...

journal_title：Cancer chemotherapy and pharmacology

authors： Guo CB,Li YC,Jin XQ

更新日期：2006-07-01 00:00:00

abstract：:We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxifica...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen J,Adikari M,Pallai R,Parekh HK,Simpkins H

更新日期：2008-05-01 00:00:00

abstract：PURPOSE:We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity with sequence-specific dosing of 5-fluorouracil preceding tem...

journal_title：Cancer chemotherapy and pharmacology

authors： Fine RL,Gulati AP,Krantz BA,Moss RA,Schreibman S,Tsushima DA,Mowatt KB,Dinnen RD,Mao Y,Stevens PD,Schrope B,Allendorf J,Lee JA,Sherman WH,Chabot JA

更新日期：2013-03-01 00:00:00

abstract：PURPOSE:The role of the microenvironment during the initiation and progression of carcinogenesis is now realized to be of critical importance, both for enhanced understanding of fundamental cancer biology, as well as exploiting this source of relatively new knowledge for improved molecular diagnostics and therapeutics....

journal_title：Cancer chemotherapy and pharmacology

authors： Mbeunkui F,Johann DJ Jr

更新日期：2009-03-01 00:00:00

abstract：PURPOSE:To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. PATIENTS AND METHODS:A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) o...

journal_title：Cancer chemotherapy and pharmacology

authors： Feliu J,Firvida JL,Castro J,Madroñal C,Rodríguez-Jaráiz A,Salgado M,Belda-Iniesta C,Casado E,García-Mata J,González-Barón M,Oncopaz Cooperative Group.

更新日期：2009-02-01 00:00:00

abstract：PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

journal_title：Cancer chemotherapy and pharmacology

authors： Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

更新日期：2021-01-05 00:00:00

abstract：:A total of 135 patients with hepatocellular carcinoma (HCC) were treated by intra-arterial injection of an Adriamycin/mitomycin C oil (lipiodol) suspension (ADMOS) alone or of ADMOS plus cis-diammine-dichloroplatinum (CDDP). In all, 59 patients were treated with ADMOS alone and 76 were treated with ADMOS plus CDDP. A ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ikeda K,Inoue H,Yano T,Kobayashi H,Nakajo M

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:To investigate any effect of a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) on cediranib steady-state pharmacokinetics in patients with advanced solid tumours. METHODS:In two Phase I, open-label trials, patients received once-daily oral doses of cediranib alone [20 mg (ketoconazole study); 45 mg (ri...

journal_title：Cancer chemotherapy and pharmacology

authors： Lassen U,Miller WH,Hotte S,Evans TR,Kollmansberger C,Adamson D,Nielsen DL,Spicer J,Chen E,Meyer T,Brown K,Rafi R,Sawyer MB

更新日期：2013-02-01 00:00:00

abstract：:Studies are described in which a new folate analogue, edatrexate (EDX), in combination with the vinca alkaloids, vinblastine (VBL), navelbine (NVB) or vindesine (DVA) was evaluated against E0771 mammary adenocarcinoma, T241 fibrosarcoma and the Lewis lung tumor. Each of the four agents when given individually to anima...

journal_title：Cancer chemotherapy and pharmacology

authors： Otter GM,Sirotnak FM

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates. METHODS:Patients progressive to cisplatin-based chemotherapy were enrolled. Irinotecan 180 mg/m(2), folinic acid 200 m...

journal_title：Cancer chemotherapy and pharmacology

authors： Lorizzo K,Fazio N,Radice D,Boselli S,Ariu L,Zampino MG,Nolè F,Magni E,Ardito R,Minchella I,Rocca A,Di Meglio G,Squadroni M,de Braud F

更新日期：2009-07-01 00:00:00

abstract：BACKGROUND:Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the upregulation of specific tra...

journal_title：Cancer chemotherapy and pharmacology

authors： Trojel-Hansen C,Erichsen KD,Christensen MK,Jensen PB,Sehested M,Nielsen SJ

更新日期：2011-07-01 00:00:00

abstract：:The cytotoxic action of 5-aza-2'-deoxycytidine (5-AZA-CdR) in synchronized cells and logarithmic- and plateau-phase cultures of EMT6 murine tumor cells was investigated. 5-AZA-CdR produced a greater cell kill of S phase cells than of cells in G1 phase. Cells in the logarithmic phase of growth were more sensitive to th...

journal_title：Cancer chemotherapy and pharmacology

authors： Momparler RL,Samson J,Momparler LF,Rivard GE

更新日期：1984-01-01 00:00:00

abstract：:A series of halogen analogs of phosphoramide mustard, isophosphoramide mustard, and triphosphoramide mustard, the cytotoxic metabolites of the antitumor drugs cyclophosphamide, ifosfamide, and trofosfamide, respectively, was evaluated in vitro against human tumor cell lines and in vivo against experimental tumors to i...

journal_title：Cancer chemotherapy and pharmacology

authors： Struck RF,Schmid SM,Waud WR

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor receptor 2 (HER2)-negative MBC are still limited. Therefore, we conducted a phase II trial to investigate the efficacy and safety of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kimura K,Iwamoto M,Tanaka S,Yamamoto D,Yoshidome K,Ogura H,Terasawa R,Matsunami N,Takahashi Y,Nitta T,Morimoto T,Fujioka H,Kawaguchi K,Uchiyama K

更新日期：2018-05-01 00:00:00